Covenant Partners’s BioMarin Pharmaceuticals BMRN Stock Holding History

Covenant Partners’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-3,054	Closed	-$231K	–	202
2021 Q1	$231K	Buy	+3,054	New	+$249K	0.09%	179
2020 Q4	–	Sell	-2,932	Closed	-$223K	–	184
2020 Q3	$223K	Sell	2,932 -766	-21%	-$77.5K	0.11%	175
2020 Q2	$456K	Buy	+3,698	New	+$368K	0.21%	111
2020 Q1	–	Sell	-3,891	Closed	-$329K	–	192
2019 Q4	$329K	Buy	+3,891	New	+$294K	0.15%	143
2019 Q3	–	Sell	-3,819	Closed	-$327K	–	182
2019 Q2	$327K	Buy	3,819 +732	+24%	+$62.6K	0.17%	138
2019 Q1	$274K	Buy	+3,087	New	+$286K	0.15%	154

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Covenant Partners's BMRN Position: Q2 2021 in Review

Covenant Partners sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2021, closing a stake of 3,054 shares — an estimated $231K sold.

Covenant Partners first reported a position in BMRN in Q1 2019 and held it in 6 quarters. The position peaked at $456K in Q2 2020. 529 funds tracked by Wall St. Rank hold BMRN as of Q2 2021.

Covenant Partners reported no remaining BioMarin Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
Covenant Partners sold 3,054 BioMarin Pharmaceuticals shares in Q2 2021, an estimated $231K.
Covenant Partners first reported a position in BioMarin Pharmaceuticals in Q1 2019 and held it in 6 quarters.
Covenant Partners's BioMarin Pharmaceuticals position peaked at $456K in Q2 2020.
529 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2021.

Based on Covenant Partners's 13F filing for Q2 2021, filed 2 Aug 2021.